Want to see DE:MAK full AI Analyst Report?

MATERNUS-Kliniken AG (MAK) Price & Analysis

2 Followers

MAK Stock Chart & Stats

€0.92

€0.01(0.99%)

At close: Jul 27 4:00 PM EDT

€0.92

€0.01(0.99%)

Day’s Range― - ―

52-Week Range€0.81 - €10.90

Previous CloseN/A

Volume24.00

Average Volume (3M)2.80K

Market Cap

€19.40M

Enterprise Value€135.05

Total Cash (Recent Filing)€5.35M

Total Debt (Recent Filing)€183.19M

Price to Earnings (P/E)―

Beta0.53

Next Earnings

Apr 23, 2027

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.76

Shares Outstanding20,970,000

10 Day Avg. Volume8,043

30 Day Avg. Volume2,798

Financial Highlights & Ratios

PEG Ratio-0.32

Price to Book (P/B)-0.27

Price to Sales (P/S)0.18

P/FCF Ratio1.92

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Recurring Care RevenueThe residential care model is built around recurring fees from occupied facilities, supported by insurance benefits, resident contributions and social assistance where applicable. This revenue structure can provide a durable base for operations because care needs persist over time rather than depending solely on discretionary demand.

Positive Cash GenerationPositive operating cash flow across the reported years and improving free cash flow in 2025 show that the facilities are generating cash despite reported accounting losses. This supports ongoing operations and may provide some funding for investment, although the current cash generation remains insufficient to rapidly reduce debt.

Narrowing LossesThe improvement in losses and the modestly better EBIT result compared with earlier periods indicate some operational progress within a difficult earnings profile. If sustained, this trend could improve internal funding capacity and reduce the gap between cash generation and reported profitability over coming quarters.

Bears Say

Sharp Revenue DeclineA revenue decline of roughly one-third materially weakens the scale benefits of a facility-based care model and raises concerns about demand, occupancy, pricing or service mix. Lower revenue makes it harder to absorb fixed operating costs, sustain margins and generate enough cash to address the company’s financial obligations.

Highly Strained Balance SheetNegative shareholders’ equity reflects an impaired capital base and leaves the company with limited financial flexibility. Debt exceeding the asset base increases refinancing and covenant risk, while the weak balance sheet can restrict investment capacity and make the business more vulnerable if operating performance deteriorates.

Persistent UnprofitabilityPersistent net losses and negative operating margins show that the core business has not yet converted its revenue base into sustainable profitability. Continued losses can erode the capital base, limit internally funded growth and reduce the company’s ability to withstand cost pressure or weaker facility performance.

MAK FAQ

What was MATERNUS-Kliniken AG’s price range in the past 12 months?

MATERNUS-Kliniken AG lowest stock price was €0.81 and its highest was €10.90 in the past 12 months.

What is MATERNUS-Kliniken AG’s market cap?

MATERNUS-Kliniken AG’s market cap is €19.40M.

When is MATERNUS-Kliniken AG’s upcoming earnings report date?

MATERNUS-Kliniken AG’s upcoming earnings report date is Apr 23, 2027 which is in 205 days.

How were MATERNUS-Kliniken AG’s earnings last quarter?

MATERNUS-Kliniken AG released its earnings results on Aug 20, 2026. The company reported -€0.091 earnings per share for the quarter.

Is MATERNUS-Kliniken AG overvalued?

According to Wall Street analysts MATERNUS-Kliniken AG’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does MATERNUS-Kliniken AG pay dividends?

MATERNUS-Kliniken AG does not currently pay dividends.

What is MATERNUS-Kliniken AG’s EPS estimate?

MATERNUS-Kliniken AG’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does MATERNUS-Kliniken AG have?

MATERNUS-Kliniken AG has 20,970,000 shares outstanding.

What happened to MATERNUS-Kliniken AG’s price movement after its last earnings report?

MATERNUS-Kliniken AG reported an EPS of -€0.091 in its last earnings report. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of MATERNUS-Kliniken AG?

Currently, no hedge funds are holding shares in DE:MAK

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

MATERNUS-Kliniken AG Stock Smart Score

Neutral

Technicals

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

MATERNUS-Kliniken AG

Maternus-Kliniken AG oversees a network of facilities that includes retirement and nursing residences, rehabilitation centers, and a variety of specialized service companies. This enterprise primarily focuses on delivering geriatric care and medical rehabilitation services. Furthermore, it offers an extensive range of support options, such as emergency response systems, assisted living arrangements, and various care modalities including home care, residential care, temporary stays, and care for individuals with disabilities. Its services also encompass comprehensive rehabilitation and post-treatment programs. The company maintains roughly 23 establishments throughout Germany. Founded in 1877, Maternus-Kliniken AG's corporate headquarters are situated in Berlin, Germany.